261 related articles for article (PubMed ID: 12060609)
1. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies.
Spiridon CI; Guinn S; Vitetta ES
Clin Cancer Res; 2004 May; 10(10):3542-51. PubMed ID: 15161714
[TBL] [Abstract][Full Text] [Related]
3. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
[TBL] [Abstract][Full Text] [Related]
4. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
5. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
6. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
10. New HER2-directed therapies for breast cancer. Commentary re: C. I. Spiridon et al., Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity. Clin. Cancer Res., 8: 1720-1730, 2002.
Frankel AE
Clin Cancer Res; 2002 Jun; 8(6):1699-701. PubMed ID: 12060606
[No Abstract] [Full Text] [Related]
11. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
13. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
[TBL] [Abstract][Full Text] [Related]
17. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.
Pratesi G; Petrangolini G; Tortoreto M; Addis A; Zunino F; Calcaterra C; Merlo A; Tagliabue E; Menard S; Balsari A
J Immunother; 2008; 31(6):537-44. PubMed ID: 18528301
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
